Clinical trials
Metastatic Pancreatic Ductal Adenocarcinoma clinical trials
Below are recruiting metastatic pancreatic ductal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 157 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06984562Recruiting
Adaptive radiation therapy for advanced pancreatic cancer
This trial tests a new way of giving radiation therapy that adapts to changes in your cancer over time. It is for people with pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06892054RecruitingPhase 1
Targeted therapy plus chemo for advanced pancreatic cancer
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
Avignon, FranceAges 18 years+ - NCT06600906Recruiting
MRI test to predict treatment response in pancreatic cancer
This study is testing a new MRI technique that may help predict how well pancreatic cancer treatments will work. You would receive a special substance (called hyperpolarized pyruvate) during a standard MRI scan.
San Francisco, CaliforniaAges 18 years+ - NCT06825546RecruitingPhase 2
Icaritin plus chemo for advanced pancreatic cancer
This trial tests a new combination of a plant-based drug (icaritin) and two chemotherapy drugs (AG) for people with advanced pancreatic cancer who have not had treatment before. The goal is to see if the combination works better than chemotherapy alone.
Guangzhou, GuangdongAges 18–80 - NCT06393400RecruitingPhase 1
Stool transplant with chemotherapy for advanced pancreatic cancer
This study tests if giving patients a stool transplant (also called FMT) in capsules along with their first chemotherapy can help treat advanced pancreatic cancer that cannot be removed by surgery.
London, OntarioAges 18 years+ - NCT07252076Recruiting
MRI for detecting hidden liver metastases in pancreatic cancer
This trial uses an MRI scan to look for small liver metastases that may not be visible on a CT scan in people newly diagnosed with pancreatic cancer. It aims to improve the accuracy of staging before treatment begins.
Alessandria, PiedmontAges 18 years+ - NCT06261359RecruitingPhase 2
CEND-1 plus chemo for first-line pancreatic cancer
This trial tests a new drug called CEND-1 combined with standard chemotherapy for people with advanced pancreatic cancer that has not been treated before. It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–80 - NCT07096362RecruitingPhase 2
Using a blood test to guide treatment for advanced pancreatic cancer
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
Miami, FloridaAges 18 years+ - NCT06574620Recruiting
Studying tumor DNA and proteins in pancreatic cancer
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
Vancouver, British ColumbiaAges 18 years+ - NCT06967662Enrolling by invitation
Plasma Adsorption to Prevent Pancreatic Cancer Spread During Surgery
This trial tests whether a special blood-filtering treatment (plasma adsorption to remove extracellular DNA) given during surgery can help prevent pancreatic cancer from spreading. It is for people with non-metastatic pancreatic cancer who are scheduled for surgery.
Moscow, Moscow OblastAges 18–75 - NCT07163273RecruitingPhase 2
Alternating chemotherapy for first-line metastatic pancreatic cancer
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
Bay Shore, New YorkAges 18 years+ - NCT05472259RecruitingPhase 2
Testing two chemotherapy combos for metastatic pancreatic cancer
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
Antwerp, AntwerpAges 18 years+ - NCT07101679RecruitingPhase 2
Study of radiation, chemo, and immunotherapy for advanced pancreatic cancer
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–75 - NCT07217717RecruitingPhase 3
New PET scan for pancreatic cancer staging
This study tests a new type of PET scan that uses a radioactive tracer called FAPI-74 to find cancer spread in people with pancreatic cancer. The goal is to see if this scan can help doctors better plan treatment.
Cerritos, CaliforniaAges 18 years+ - NCT07235202RecruitingPhase 1/Phase 2
MR001 plus chemo for advanced pancreatic cancer after first treatment
This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07723261Recruiting
Testing NalIriFOx as first treatment for metastatic pancreatic cancer
This trial is testing a drug combination called NalIriFOx as the first treatment for people with pancreatic cancer that has spread. The goal is to see if it is safe and works well over the long term.
AthensAges 18 years+ - NCT07408505Recruiting
New appetite drug for weight loss in advanced pancreatic cancer
This trial tests a new form of a drug (nano-megestrol acetate) to help people with advanced pancreatic cancer who are losing weight and have poor appetite. It aims to see if it can improve cachexia, a condition of severe weight loss and muscle wasting.
JinanAges 18–75 - NCT07047807Recruiting
Digital support app for pancreatic cancer patients starting treatment
This trial tests a smartphone app designed to provide information and support to people with pancreatic cancer who are about to start neoadjuvant therapy before surgery. The app aims to help you manage your care and feel more supported during this time.
Boston, MassachusettsAges 18 years+ - NCT07241676Enrolling by invitation
Pancreatic cancer surgery and early recurrence study
This study looks at patients who had surgery to remove pancreatic cancer to understand what factors might lead to the cancer coming back early. If you have had surgery for pancreatic cancer and are interested in helping researchers learn more, this may be a fit.
Padova, PDAges 18 years+ - NCT07165951RecruitingPhase 3
Study of new drug combo for first treatment of advanced pancreatic cancer
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
Hefei, AnhuiAges 18–75 - NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+ - NCT07483983RecruitingPhase 2
Study of ASP3082 for advanced lung and pancreatic cancers with KRAS G12D mutation
This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.
Villejuif, FranceAges 18 years+ - NCT07252232RecruitingPhase 3
A pill to prevent pancreatic cancer recurrence after surgery
This trial tests an experimental daily pill, daraxonrasib, in people with pancreatic cancer that has been surgically removed. It’s for those who also had chemotherapy and have a specific DNA change called a RAS mutation. The goal is to see if the pill helps prevent the cancer from coming back.
Phoenix, ArizonaAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Birmingham, AlabamaAges 18 years+
Hear when a new Metastatic Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic pancreatic ductal adenocarcinoma?
- Yes. Clin2 currently lists 157 recruiting metastatic pancreatic ductal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic pancreatic ductal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic pancreatic ductal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (mPDAC)
- Resectable Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.